TAT-11: Investigation of Monocarbon Carboranes as Pendant Groups for Labeling Small Molecules with Astatine-211
Ottawa, ON, Canada (UroToday.com) Dr. Li motivated the search for new labeling compounds by noting that previous experiences with Biotin as a carrier were not very successful since it exited the body before saturating the tumor. As alternatives, Dr. Li described the development of two monocarbon carboranes. One of these, 1-(p-Bz)-closo-CB9H8-OH, when labeled with At211 provides high radiochemical yields in vivo stability is being evaluated.
Presented by: Yawen Li, PhD, University of Washington-Seattle, Seattle, Washingto, United States
Written by: William Carithers, Lawrence Berkeley National Laboratory at the 11th International Symposium on Targeted Alpha Therapy (TAT-10) April 1 - April 4, 2019 - Ottawa, ON, Canada